1. Home
  2. AXIL vs IMMP Comparison

AXIL vs IMMP Comparison

Compare AXIL & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AXIL Brands Inc.

AXIL

AXIL Brands Inc.

N/A

Current Price

$6.27

Market Cap

39.5M

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.26

Market Cap

42.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXIL
IMMP
Founded
2015
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.5M
42.4M
IPO Year
2017
2012

Fundamental Metrics

Financial Performance
Metric
AXIL
IMMP
Price
$6.27
$0.26
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
★ $5.50
AVG Volume (30 Days)
18.2K
★ 324.8K
Earning Date
04-08-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 230.00
N/A
EPS
★ 0.33
N/A
Revenue
★ $30,847,570.00
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
$18.76
★ N/A
Revenue Growth
★ 17.48
N/A
52 Week Low
$4.28
$0.26
52 Week High
$9.86
$3.53

Technical Indicators

Market Signals
Indicator
AXIL
IMMP
Relative Strength Index (RSI) 52.43 29.26
Support Level $6.02 N/A
Resistance Level $7.39 $0.40
Average True Range (ATR) 0.24 0.02
MACD 0.01 -0.01
Stochastic Oscillator 78.65 7.86

Price Performance

Historical Comparison
AXIL
IMMP

About AXIL AXIL Brands Inc.

AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, and outdoor speakers, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering. The company operates two operating segments: hearing enhancement and protection, and hair and skin care.

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: